Fortrea Akan Mengakuisisi Unit Farmakologi Klinis dan Operasional Laboratorium Bionalitik dari Worldwide Clinical Trials

Fortrea has signed a definitive agreement to acquire the Early Phase Services division from Worldwide Clinical Trials for approximately $45 million. The acquisition includes bioanalytical laboratories in Austin, a 200-bed clinical pharmacology unit in San Antonio, and biospeci­men storage facilities in Pflugerville, Texas. This deal strengthens Fortrea's early-stage clinical development platform and integrated capabilities, while allowing Worldwide to focus on its faster-growing late-stage business across oncology, neuroscience, and rare diseases.

09/03/2026, 3:52 AM • GlobeNewswire

フォートリア、ワールドワイド・クリニカル・トライアルズから臨床薬理部門およびバイオアナリシスラボ事業を買収

Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP-compliant bioanalytical lab in Austin, a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, and a biorepository facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform from Phase I through Phase IV trials, while allowing Worldwide to focus on its rapidly growing late-stage business in oncology, neuroscience, internal medicine, and rare diseases.

09/03/2026, 3:52 AM • GlobeNewswire

Fortrea, Worldwide Clinical Trials의 임상약리 유닛·생물분석 연구소 사업 인수

Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP-compliant bioanalytical laboratory in Austin, a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, and biospecimen storage facilities in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform from Phase 1 through Phase 4 trials and post-approval evidence generation, while allowing Worldwide to focus on its faster-growing late-stage clinical business in oncology, neuroscience, internal medicine, and rare diseases.

09/03/2026, 3:52 AM • GlobeNewswire

Fortrea תרכוש את היחידה לפרמקולוגיה קלינית ואת פעילות המעבדה הביו-אנליטית של Worldwide Clinical Trials

Fortrea has signed a definitive agreement to acquire Worldwide Clinical Trials' Early Phase Services division for approximately $45 million in cash. The acquisition includes a GLP-compliant bioanalytical laboratory in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biological sample storage facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform and early-stage capabilities, while allowing Worldwide to focus on its rapidly growing late-stage development business in oncology, neuroscience, internal medicine, and rare diseases.

09/03/2026, 3:52 AM • GlobeNewswire

Fortrea acquiert l’unité de pharmacologie clinique et les activités de laboratoire bioanalytique de Worldwide Clinical Trials

Fortrea has agreed to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP-compliant bioanalytical laboratory in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biological sample storage facility in Pflugerville, Texas. This strengthens Fortrea's end-to-end clinical development platform with integrated bioanalytical capabilities for both large and small molecules, while allowing Worldwide to focus on its growing advanced-stage development activities in oncology, neurosciences, internal medicine, and rare diseases.

09/03/2026, 3:52 AM • GlobeNewswire

Fortrea 將收購 Worldwide Clinical Trials 的臨床藥理學部門及生物分析實驗室業務

Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP bioanalytical lab in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biosampling facility in Frugerville, Texas. The deal strengthens Fortrea's end-to-end clinical development platform and early-stage capabilities, while allowing Worldwide to focus on its rapidly growing late-stage business in oncology, neuroscience, internal medicine, and rare diseases.

09/03/2026, 3:52 AM • GlobeNewswire

Fortrea Akan Mengambil Alih Unit Farmakologi Klinikal dan Operasi Makmal Bioanalisis daripada Worldwide Clinical Trials

Fortrea has signed a definitive agreement to acquire Worldwide Clinical Trials' Early Phase Services division for approximately $45 million. The acquisition includes a GLP bioanalytical lab in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biospecimen storage facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform and expands its early-phase capabilities, while allowing Worldwide to focus on its rapidly growing late-phase business in oncology, neuroscience, and rare diseases.

09/03/2026, 3:52 AM • GlobeNewswire

Fortrea übernimmt Einheit für klinische Pharmakologie und bioanalytische Laboraktivitäten von Worldwide Clinical Trials

Fortrea hat eine verbindliche Vereinbarung zum Erwerb des Geschäftsbereichs 'Frühe klinische Entwicklung' von Worldwide Clinical Trials für etwa 45 Millionen US-Dollar abgeschlossen. Die Übernahme umfasst ein GLP-konformes bioanalytisches Labor in Austin, eine klinisch-pharmakologische Abteilung mit 200 Betten in San Antonio und ein Bioprobenlager in Texas. Dies stärkt Fortreas Position als führender globaler Partner für klinische Entwicklung und ermöglicht integrierte Lösungen für frühe klinische Phasen.

09/03/2026, 3:52 AM • GlobeNewswire

Fortrea 将收购 Worldwide Clinical Trials 的临床药理部门和生物分析实验室业务

Fortrea has signed a definitive agreement to acquire Worldwide Clinical Trials' Early Phase Services division for approximately $45 million in cash. The acquisition includes a GLP bioanalytical lab in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biosampling facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform and early-stage capabilities, while allowing Worldwide to focus on its faster-growing late-stage business in oncology, neuroscience, internal medicine, and rare diseases.

09/03/2026, 3:52 AM • GlobeNewswire

Fortrea Adquire Unidade de Farmacologia Clínica e Operações de Laboratório Bioanalítico da Worldwide Clinical Trials

Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in cash. The acquisition includes a GLP-certified bioanalytical laboratory in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biosampling storage facility in Pflugerville, Texas. This strategic move strengthens Fortrea's early-stage clinical development platform and enables integrated Phase I-IV services, while allowing Worldwide to focus on its rapidly growing advanced-stage development business in oncology, neurociencia, and rare diseases.

09/03/2026, 3:52 AM • GlobeNewswire

Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Fortrea has signed a definitive agreement to acquire Worldwide Clinical Trials' Early Phase Services division for approximately $45 million in an all-cash transaction. The acquisition includes a 60,000 sq. ft. GLP bioanalytical lab in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biospecimen storage facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform and early-phase capabilities, while allowing Worldwide to focus on its rapidly growing late-stage business across oncology, neuroscience, internal medicine, and rare disease.

09/02/2026, 7:00 AM • GlobeNewswire

Global Clinical Trials Market to Reach $176.32 Billion by 2030 as AI and Decentralized Research Accelerate Growth

The global clinical trials market is projected to grow from $127.16 billion in 2025 to $176.32 billion by 2030, with a CAGR of 6.8%. Growth is driven by AI-enabled trial design, decentralized and virtual trials, precision medicine, and real-world evidence studies. North America leads the market while Asia-Pacific is the fastest-growing region. Strategic consolidation continues with major acquisitions strengthening end-to-end capabilities.

07/15/2026, 6:46 AM • GlobeNewswire

Fortrea to Attend Jefferies Global Healthcare Conference

Fortrea (Nasdaq: FTRE), a leading global contract research organization, announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations Tracy Krumme will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026. The company reported strong first-quarter 2026 performance with a book-to-bill ratio of 1.15x, marking the third consecutive quarter above 1.1x.

06/02/2026, 6:00 PM • GlobeNewswire

Fortrea 推出 Fortrea Intelligent Technology™ 以助贊助商及研究中心進行更智能、更整合的試驗

Fortrea, a leading global clinical research organization, announced the launch of Fortrea Intelligent Technology (FIT), an AI-powered solution designed to automate workflows and streamline clinical trial operations. Built on the Xcellerate® platform, FIT offers three pillars: full lifecycle trial management, data-driven foresight analytics, and AI-powered companion tools to improve trial speed, predictability, and quality for sponsors and research sites.

04/07/2026, 10:28 PM • GlobeNewswire

Fortrea dévoile Fortrea Intelligent Technology™ : une technologie destinée à permettre aux investigateurs et aux centres d’essais cliniques de mener des essais plus intelligents et mieux intégrés

Fortrea, a leading global contract research organization, announced the launch of Fortrea Intelligent Technology (FIT), an AI-powered suite of solutions designed to revolutionize clinical trial processes. FIT automates workflows, streamlines oversight, and improves productivity for investigators, clinical trial centers, and research teams. The platform builds on Fortrea's flagship Xcellerate® platform and incorporates AI and machine learning to analyze complex patterns, generate predictive signals, and reduce manual tasks while enabling faster decision-making and risk management.

04/07/2026, 10:28 PM • GlobeNewswire